$RXRX News

Recursion (RXRX) Q2 2026 Earnings Call Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript

Recursion Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Recursion Pharmaceuticals Q2 Earnings Call Highlights

Recursion Pharmaceuticals (RXRX) Is Up 11.4% After Mixed Q2 Results And Genentech Milestone Update

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call Transcript

Recursion Pharmaceuticals (RXRX) Stock Still Looks Expensive Following August 5 Results Update

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Recursion Pharmaceuticals Q2 EPS $(0.25) Misses $(0.22) Estimate, Sales $7.670M Miss $11.947M Estimate

Recursion to Participate in Upcoming Investor Conferences

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know

Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today

Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?

Recursion Pharmaceuticals: Short-Trade Crowded But Near-Term Squeeze Not Guaranteed

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript